Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from March 27, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on June 25, 2026 — +25.6% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$880.00 – $910.00Entry zone — fair-value band

$897.99Published — price the day we called it

$1,041.67Target — the price the thesis aimed for

$1,182.73Peak — highest point inside the window, not a realized return

$1,127.69Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 55 days.

At window close

+25.6%

realized, from the publication price to the last close inside the window

Peak gain

+31.7%

peak, from the publication price — not a realized return

S&P 500, same window

+16.1%

SPY over the identical days, dividend-adjusted

Window close

$1,127.69

last close inside the window, ended June 25, 2026

Peak price

$1,182.73

peak on June 8, 2026 — not a realized return

Days to target

The thesis — published March 27, 2026

Predicted growth

+16%

over the measurement window

Target price

$1,041.67

the price the thesis aimed for

Entry zone

$880.00 – $910.00

the fair-value band we waited for

Price at publication

$897.99

published March 27, 2026

Confidence

80%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Lilly is a big drug company with steady sales and strong recent performance. A recent price dip makes it more attractive because its main businesses-diabetes, obesity, and immunology-are performing well and new EBGLYSS durability data expands confidence beyond just obesity. Health stocks often hold up when markets wobble, and Lilly still shows reliable earnings strength.

Primary drivers

Clear leadership in diabetes and obesity treatments
Reliable earnings and operational execution
New EBGLYSS data extends clinical momentum
Healthcare stocks often hold up in volatile markets

How it played out

LLY: target reached in 55 days

At publication, LLY was 897.99 and the thesis expected 16% short-term growth. The thesis pointed to leadership in diabetes and obesity treatments, reliable earnings and execution, new EBGLYSS durability data, and the tendency of healthcare stocks to hold up when markets were volatile.

Within the window, LLY reached the 1041.67 target after 55 days. It peaked at 1182.73 on June 8, a 31.7% gain, then ended at 1127.69 on June 25. The published thesis played out and the stock exceeded its target.

What happened during the window

On April 30, 2026, Lilly reported first-quarter revenue of $19.8 billion and raised its full-year guidance. On May 31, 2026, Lilly announced Phase 3 results for Retevmo in early-stage lung cancer.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals